R

RAPT Therapeutics
D

RAPT

7.37000
USD
0.00
(0.00%)
Market Closed
Volume
4,478
EPS
-3
Div Yield
-
P/E
-0
Market Cap
121,870,946
Related Instruments
ABBV
ABBV
-0.290
(-0.16%)
185.210 USD
AMGN
AMGN
-0.10
(-0.03%)
289.40 USD
BIIB
BIIB
0.480
(0.38%)
127.050 USD
BMY
BMY
0.005
(0.01%)
46.860 USD
GILD
GILD
-0.020
(-0.02%)
108.000 USD
JNJ
JNJ
-0.970
(-0.64%)
149.760 USD
MRK
MRK
-0.180
(-0.23%)
79.110 USD
PFE
PFE
0.085
(0.36%)
23.970 USD
REGN
REGN
-3.73
(-0.73%)
509.70 USD
More
News

Title: RAPT Therapeutics Inc

Sector: Healthcare
Industry: Biotechnology
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cellsinto inflamed tissues.
Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.